passages: 3386
passages: document
passages: Role of angiotensin-converting enzyme inhibitors in early antihypertensive treatment in non-insulin dependent diabetes mellitus . The effect of captopril monotherapy on blood pressure and metabolism was investigated in a placebo-controlled study in 30 non-insulin dependent ( Type II ) diabetic subjects during a 3-week observation period ( run-in/drug ; placebo/wash-out ) on a metabolic ward . Captopril significantly reduced both systolic and diastolic blood pressure ( 154/90 +/- 5/2 vs. 144/86 +/- 4/3 mmHg ) without major side effects . Mean run-in postprandial blood glucose concentrations were also reduced upon ACE-inhibition ( 9 a.m. : 12.7 +/- 0.4 vs. 11.1 +/- 0.4 mmol/l ; 1 p.m. : 11.0 +/- 0.3 vs. 8.9 +/- 0.3 mmol/l ; P less than 0.05 ) , while blood kinin concentrations ( 40.0 +/- 2.5 pmol/l ) were approximately doubled ( 108.8 +/- 23.5 pmol/l ; P less than 0.05 ) . Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile as well as hepatic and renal function parameters remained unaltered throughout the observation period . The data are in line with recent experimental studies showing a beneficial metabolic effect of captopril in Type II diabetes . ACE inhibitors might therefore become first-line drugs in early antihypertensive intervention in Type II diabetic patients .
entities: 3387
entities: Intervention_Pharmacological
entities: angiotensin-converting enzyme inhibitors
entities: 3388
entities: Intervention_Pharmacological
entities: captopril
entities: 3389
entities: Intervention_Control
entities: placebo-controlled
entities: 3390
entities: Intervention_Pharmacological
entities: Captopril
entities: 3391
entities: Intervention_Pharmacological
entities: captopril
entities: 3392
entities: Intervention_Pharmacological
entities: ACE inhibitors
entities: 3393
entities: Outcome_Physical
entities: blood pressure
entities: 3394
entities: Outcome_Physical
entities: metabolism
entities: 3395
entities: Outcome_Physical
entities: systolic and diastolic blood pressure
entities: 3396
entities: Outcome_Physical
entities: postprandial blood glucose concentrations
entities: 3397
entities: Outcome_Physical
entities: blood kinin concentrations
entities: 3398
entities: Outcome_Physical
entities: Body mass index , fasting plasma insulin , serum electrolyte pattern , uric acid , white blood count , lipid profile
entities: 3399
entities: Outcome_Physical
entities: hepatic and renal function
entities: 3400
entities: Participant_Condition
entities: non-insulin dependent diabetes mellitus .
entities: 3401
entities: Participant_Sample-size
entities: 30
entities: 3402
entities: Participant_Condition
entities: non-insulin dependent ( Type II ) diabetic subjects
entities: 3403
entities: Participant_Condition
entities: Type II diabetic